Human iPSC-derived Hepatocytes and Cardiomyocytes for Drug Toxicity Testing
Poster Mar 30, 2015
AnnandRR; Vardaro R; Hamilton B; Akakira R; Tamura K; Yoshida S; Lin YC; Toyoda D; Kogami H; Okuda Y; Watanabe T; Inamura M
Pharmaceutical candidate compounds require an extended period of time and high development costs before reaching the market. However, for various reasons, a high number of the candidate compounds are eliminated in the development process. The candidate compound elimination is frequently based on hepatotoxicity and cardiotoxicity. Although human primary cells are widely used for drug toxicity testing, they have posed issues such as lot-to-lot variation. Moreover, it is difficult to perform long-term tests with the same donor when using human primary cells due to the limited supply.
Human iPSC-derived hepatocytes ReproHepato™ cells were cultivated on 96-well plates, and the cells were exposed to five representative toxic compounds: acetaminophen, amiodarone, cyclophosphamide, diclofenac, and flutamide. Using conventional assays to measure ATP and LDH, we observed dose-dependent toxicity, and each compound showed IC50 values similar to the cytotoxicity observed using primary human hepatocytes (PHHs). Furthermore, we also observed toxicity using high content analysis, which simultaneously measures cell number, reduction in glutathione level, active oxygen, and mitochondrial membrane potential. These results show that ReproHepato can be used as an alternative to PHHs for routine cytotoxicity testing.
We cultivated Human iPSC-derived cardiomyocytes ReproCardio 2™ cells on 96-well plates, and exposed the cells to five representative toxic compounds: aspirin, verapamil, isoproterenol, E-4031 and flecainide. Upon the addition of chemical compounds, the prolongation or reduction of the field potential duration was observed in a Multi-Electrode Array (MEA) experiment, with small lot-to-lot variation. These results demonstrate that ReproCardio 2 is a suitable model system for in vitro cardiotoxicity screening for QT prolongation and arrhythmia potential.
In summary, human iPSC-derived hepatocytes and cardiomyocytes can be used for drug toxicity testing, as alternative sources of human primary cells.
Regulatory T-Cells (Tregs) Within Bone Marrow-Derived Stem Cells (BMSCs) Actively Confer Immunomodulatory and Neuroprotective Effects Against StrokePoster
We found a distinct subpopulation of Tregs within BMSCs. Tregs and BMSCs in co-culture conferred neuroprotection that varied in a dose-dependent manner. Tregs minimized stem cell production of IL-6, a pro-inflammatory cytokine, and inhibited BMSC secretion of FGF-beta, a cytokine related to BMSC proliferation and differentiation. The ratio of Tregs found natively in BMSCs is optimally adapted to provide the maximum neuroprotective benefit of stem cell treatment after ischemic stroke.READ MORE
Internet-Based Biomarker Collection Feasibility: Experiences of a Tobacco Cessation Program for People Living with HIVPoster
This project introduces video-conferencing as a method for biomarker collection in research and will explain how biomarker collection via video-conferencing was implemented in a pilot ehealth intervention.READ MORE
Knockout of microRNAs Using the CRISPR-Cas9 System with Paired Synthetic crRNAsPoster
We utilized paired synthetic crRNAs coupled with our synthetic tracrRNA in cells transduced with lentiviral Cas9 to perform a functional knockout on hsa-miR-221. This three-part system (crRNA, tracrRNA and Cas9) has demonstrated efficient gene editing when used with only one guide RNA, but the goal was to use two crRNAs to remove the entire stem-loop.READ MORE